TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: SANOFICONR · data 2026-11-02
Sanofi Consumer Healthcare India Limited
In plain words
Price: 33.4% below its 52-week high of ₹5,255.
Delivery: 59.9% of traded shares were kept for delivery over the last 10 sessions, against 57.0% over the last 60.
Latest results: a net profit of ₹77 cr for the quarter ended Sept 2026 (+21.8% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹979 cr |
| Net profit (last 12 months) | ₹280 cr |
| Sales growth, 3 years (yearly) | — |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 71.3% (unchanged in a year), pledged 0.0%, institutions 20.5%.
P/E 28.8, dividend yield 2.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 73.1%, ROCE 82.8%, operating margin 36.4%: how much profit it earns on the money it uses.
Debt/equity 0.06, Profit growth — and sales growth — a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (73.1%).
- Healthy operating margin (36.4%).
- Pays a dividend yielding 2.2%.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
SANOFICONR Q2 FY27 results (standalone figures, as filed on NSE).
Revenue was ₹263.1 crore, up 12.5% YoY and up 11.6% QoQ.
Net profit was ₹76.6 crore, up 21.8% YoY and up 11.3% QoQ.
Operating margin was 38.7% (36.3% a year ago).
EPS was ₹33.26, up 21.8% YoY and up 11.3% QoQ.
SANOFICONR के Q2 FY27 नतीजे (स्टैंडअलोन आंकड़े, NSE पर दाखिल)।
राजस्व: ₹263.1 करोड़; पिछले साल की तुलना में 12.5% की बढ़त, पिछली तिमाही की तुलना में 11.6% की बढ़त।
शुद्ध मुनाफ़ा: ₹76.6 करोड़; पिछले साल की तुलना में 21.8% की बढ़त, पिछली तिमाही की तुलना में 11.3% की बढ़त।
ऑपरेटिंग मार्जिन: 38.7% (एक साल पहले 36.3%)।
EPS: ₹33.26; पिछले साल की तुलना में 21.8% की बढ़त, पिछली तिमाही की तुलना में 11.3% की बढ़त।
SANOFICONRના Q2 FY27 પરિણામો (સ્ટેન્ડઅલોન આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹263.1 કરોડ; ગયા વર્ષની સરખામણીએ 12.5% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.6% વધારો.
ચોખ્ખો નફો: ₹76.6 કરોડ; ગયા વર્ષની સરખામણીએ 21.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.3% વધારો.
ઓપરેટિંગ માર્જિન: 38.7% (એક વર્ષ પહેલાં 36.3%).
EPS: ₹33.26; ગયા વર્ષની સરખામણીએ 21.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 11.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
32/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 20/30: Delivery 45.2% over the last 20 sessions vs 56.6% in the 40 before (0.8x); shares delivered per day 6.01x usual; 4 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 7/15: 8 schemes hold it, about ₹418 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 28 Oct 26Results Q2 FY27 results: profit +21.8% YoY +2.5% next session
- 28 Jul 26Results Q1 FY27 results: profit +13.3% YoY +1.3% next session
- 19 Jun 26Dividend Dividend ₹75 (ex-date) -4.6% next session
- 28 Apr 26Results Q4 FY26 results: profit +35.6% YoY +3.1% next session
- 25 Feb 26Results Q3 FY26 results: profit +50.1% YoY +14.1% next session
- 12 Nov 25Results Q2 FY26 results: profit +39.8% YoY +8.2% next session
- 4 Aug 25Results Q1 FY26 results: profit +109.3% YoY +8.9% next session
- 12 May 25Results Q4 FY25 results: net profit ₹50 cr +0.4% next session
- 17 Apr 25Dividend Dividend ₹55 (ex-date) -0.8% next session
- 21 Feb 25Results Q3 FY25 results: net profit ₹44.3 cr -3.0% next session
- 12 Nov 24Results Q2 FY25 results: net profit ₹45 cr -1.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (standalone)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹263 cr | ₹77 cr | +21.8% | 38.7% | 33.26 |
| Jun 2026 | ₹236 cr | ₹69 cr | +13.3% | 37.9% | 29.87 |
| Mar 2026 | ₹229 cr | ₹68 cr | +35.6% | 38.7% | 29.44 |
| Dec 2025 | ₹251 cr | ₹67 cr | +50.1% | 35.8% | 28.87 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 71.27% | 71.27% | 71.27% | 71.27% |
| Foreign institutions (FII) | 2.48% | 2.60% | 2.76% | 2.83% |
| Domestic institutions (DII) | 18.03% | 17.86% | 17.57% | 17.33% |
| Mutual funds | 12.92% | 13.01% | 13.63% | 13.46% |
| Retail investors | 6.16% | 6.18% | 6.26% | 6.25% |
| Number of shareholders | 46,586 | 47,511 | 48,418 | 48,075 |
Common questions
What was Sanofi Consumer Healthcare India Limited's latest quarterly profit?
Sanofi Consumer Healthcare India Limited reported a net profit of ₹77 cr for the quarter ended Sept 2026 (+21.8% on the same quarter a year earlier), on revenue of ₹263 cr.
How much do promoters hold in Sanofi Consumer Healthcare India Limited?
Promoters held 71.27% of Sanofi Consumer Healthcare India Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Sanofi Consumer Healthcare India Limited debt-free?
Its latest reported debt-to-equity ratio is 0.06, which is very low.
What is Sanofi Consumer Healthcare India Limited's P/E ratio?
About 28.8, based on the last 12 months' earnings and a price of ₹3,497.5 (data 2026-11-02).
What is the 52-week high and low of Sanofi Consumer Healthcare India Limited?
The 52-week high is ₹5,255 and the 52-week low is ₹3,168.2.
Mutual funds holding Sanofi Consumer Healthcare India Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 8 schemes holding about ₹418 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE LARGE CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.46% | ₹129 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 0.89% | ₹82 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 0.83% | ₹67 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 0.72% | ₹44 cr |
| Nippon India Innovation Fund | Nippon India Mutual Fund | 1.26% | ₹37 cr |
| ADITYA BIRLA SUN LIFE CONSUMPTION FUND | Aditya Birla Sun Life Mutual Fund | 0.52% | ₹30 cr |
| ADITYA BIRLA SUN LIFE MNC FUND | Aditya Birla Sun Life Mutual Fund | 0.62% | ₹19 cr |
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 1.11% | ₹12 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India Limited | ₹3,497.5 | ₹7,911 cr | 28.8 | — | 73.1% | 82.8% | 0.06 | -24.8% |
| Symbiotec Pharmalab Limited | ₹1,237.9 | ₹8,001 cr | — | — | — | — | — | +25.3% |
| Aarti Pharmalabs Limited | ₹887.95 | ₹7,922 cr | 31.4 | 3.6 | 8.5% | 11.5% | 0.36 | +6.2% |
| Sanofi India Limited | ₹3,289.3 | ₹7,380 cr | 20.8 | — | 40.6% | 54.6% | 0.02 | -31.5% |
| Suven Life Sciences Limited | ₹262.15 | ₹7,293 cr | — | — | -78.8% | -80.8% | 0.03 | +35.2% |
| Bliss GVS Pharma Limited | ₹626 | ₹6,894 cr | 49.6 | — | 11.5% | 10.9% | 0.02 | +300.8% |
Compare SANOFICONR with SYMBIOTEC in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SANOFICONR in TickerKhoj →